P. Lestienne et al., ROLE OF THE MITOCHONDRIAL-DNA AND CALMITINE IN MYOPATHIES, Biochimica et biophysica acta. Molecular basis of disease, 1271(1), 1995, pp. 159-163
We present data on mitochondrial DNA deletions and mitochondrial disea
ses. The mechanism of their occurrence is discussed on the basis of de
letion breakpoints and particularly with the slippage mispairing hypot
hesis. As the correlation between the genotypes and the phenotypes is
not always straightforward, a classification of mitochondrial diseases
is suggested according to the genotype (deletions, depletions and dup
lications, mutations affecting structural genes or tRNA genes) rather
than the phenotype. The effect of mitochondrial DNA alterations on the
expression of nuclear encoded proteins is presented, and the nucleus
can be found to respond differently but in a coordinate way according
to the kind of mitochondrial DNA alteration. The search for a nuclear
gene affecting the expression of Leber's disease could not show any co
rrelation between the alleles of TAP2 (transporter antigen peptide) an
d the expression of the disease. Finally, we present new data on anoth
er class of myopathies, namely Duchenne muscular dystrophy (DMD), wher
e mitochondria could play an unexpected role in the metabolism of calc
ium. In some patients with DMD a mitochondrial calcium binding protein
that is mainly located in the mitochondrial matrix and which is named
'calmitine' was found to disappear. We have thus cloned its cDNA and
found that it was identical with to calsequestrine which is a high-cap
acity but low-affinity Ca2+ binding protein from the sarcoplasmic reti
culum.